Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader
These are related to the Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader news, in which you can learn about the updated information in Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader, to help you better understand and expand Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader market. Because the market for Vazyme Releases 2022 Semi-Annual Report: On Track to Be a Biotech Leader is evolving and changing, so we recommend that you collect our website, and we will show you the latest news on a regular basis.
Revenue hit $242 million, up 96.2% y-o-y.Net profit reached $92 million, up 56.67% y-o-y.R&D investment stood at $23 million, up 85.72% y-o-y. Vazyme recently released the 2022 semi-annual report, revealing the robust growth in the first half of the year. Vazyme has been stepping up R&D efforts over
Our vision is to lead in biotechnology by driving innovation relentlessly, pursuing the highest standards in quality of products and services, and creating value for our customers.
English
简体中文